Skip to content
Menu

NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatment Of Amyotrophic Lateral Sclerosis

Benzinga Newsdesk 5 months ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents

CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).

The patent, entitled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for the unique formulation and manufacturing process of PrimeC, including its synchronized delivery profile of celecoxib and ciprofloxacin, designed to target multiple key mechanisms underlying ALS progression.

Read at benzinga.com